Mesoblast Japan Strategy Highlighted at Australia-Japan Business Council Annual Meeting
October 12, 2016 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Oct. 12, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) yesterday gave a strategic update on its product commercialization plans in Japan....
Phase 2 Trial Results of Mesoblast’s Cell Therapy in Diabetic Kidney Disease Published
October 06, 2016 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Oct. 06, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that results from the randomized, placebo-controlled Phase 2 trial...
Mesoblast Appoints Bill Burns, Former Chief Executive of Roche Pharmaceuticals, as Vice Chairman
September 01, 2016 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that Mr William (Bill) A. Burns, former Chief Executive Officer...
Mesoblast Reports Financial Results and Operational Highlights for the Three Months and for the Year Ended 30 June 2016
August 24, 2016 18:41 ET
|
Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Aug. 24, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today reported its consolidated financial results and operational highlights for the...
Mesoblast to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast
August 19, 2016 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Aug. 19, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the fourth quarter and full year...
Mesoblast Strengthens Key United States Patent Portfolio for the Treatment of Rheumatic Diseases
August 17, 2016 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that its intellectual property portfolio covering the use of its...
Phase 2 Trial Results of Mesoblast’s Cell Therapy Show Dose-Related Improvements in Biologic Refractory Rheumatoid Arthritis
August 08, 2016 19:11 ET
|
Mesoblast Limited
Key points: The biologic refractory rheumatoid arthritis (RA) population accounts for approximately one-third of all RA patients who have received anti-TNF or other biologic agents, is the fastest...
Mesoblast’s Full 24-Month Trial Results for Chronic Low Back Pain Presented at Spine Intervention Society Annual Meeting, Receive Award for Best Basic Science
August 01, 2016 06:00 ET
|
Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that the 24-month results from the 100-patient, four-arm, randomized,...
Mesoblast Provides Update on Heart Failure Trial and Funding of Clinical Operations
July 01, 2016 06:00 ET
|
Mesoblast Limited
Highlights Interim Analysis to assess heart failure Phase 3 trial’s primary endpoint to read-out meaningful data in Q1 2017 The anticipated trial costs to this Interim Analysis are...
Mesoblast Provides Update on Global Heart Failure Program
June 13, 2016 18:54 ET
|
Mesoblast Limited
Key points:Mesoblast regains worldwide rights to cardiovascular field for its cell therapy platformLead product candidate in cardiovascular portfolio is MPC-150-IM for heart failure, with multibillion...